Adding Inhibrx's OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, en...
BUSINESS NEWS
May 11, 2026
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Adding Inhibrx's OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance the program.
2 views
0 likes
0 comments
Adding Inhibrx's OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance the program.
Author: Fierce Biotech
Read Original Article
